Infectious Disease

Top Story

NIH awards $4.9 million for study of polymyxin B treatment

August 2, 2015

The National Institute for Allergy and Infectious Diseases has awarded nearly $4.9 million in funding toward the development of optimal polymyxin B treatments in critically ill patients, according to a press release.

Led by Infectious Disease News Editorial Board member Keith S. Kaye, MD, MPH, researchers from Wayne State University School of Medicine, the Sinai Grace Hospital at Detroit Medical Center, the University of North Carolina and Monash University, Australia, will work with gram-negative bacteria susceptible only to polymyxin B. Their goal is to define optimal dosage regimens to minimize the effect of nephrotoxicity, while developing a therapeutic drug monitoring system to assist physicians giving the treatment.

Kathryn Edwards In the Journals

Certain background infections may play etiologic role in CAP

August 1, 2015
Although the full clinical significance of a detected virus in a patient with community-acquired pneumonia remains unclear, recent findings suggest it likely plays a…

White House releases updated 2020 HIV/AIDS strategy

July 31, 2015
President Barack Obama has signed an executive order releasing the updated goals of the National HIV/AIDS Strategy over the next 5 years, according to a White House…
In the Journals

Chronic HBV prevalent among non-high-risk populations across world

July 31, 2015
In a new study, researchers found a prevalence of chronic hepatitis B virus infection across various non–high-risk populations across the world, indicating…
Meeting News Coverage

HBV reactivation unlikely after biologic treatment for rheumatic diseases, inflammatory bowel disease

July 31, 2015
Hepatitis B reactivation following biologic therapy for rheumatic diseases or inflammatory bowel disease was unlikely, according the recently presented study findings.A…
More News Headlines »
CME
HCV VOICE

HCV VOICE II: Optimizing Virological Outcomes with Integrated HCV Education

This activity is supported by an educational grant from Janssen Therapeutics, Division of Janssen Products, LP.

Chronic hepatitis C virus (HCV) infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular…
More »
At Issue Video
VIDEO: Cure is ‘next frontier’ of HIV

VIDEO: Cure is ‘next frontier’ of HIV

July 1, 2015
Timothy Brown – the Berlin patient – has led researchers to the next frontier of HIV research, according to…
More »
CME
Infectious Disease Case Consults

The Patient at Risk for HIV Infection

No commercial support for this activity.

This CME activity will focus on the utilization of PrEP in patients at risk for developing HIV infection supplemented…
More »